Positron emission tomography and computed tomography with [68Ga]Ga-fibroblast activation protein inhibitors improves tumor detection and staging in patients with …
Y Pang, L Zhao, Q Shang, T Meng, L Zhao… - European journal of …, 2022 - Springer
Purpose This study aimed to investigate the diagnostic performance of [68 Ga] Ga-FAPI
PET/CT for primary and metastatic pancreatic carcinoma lesions and compare the results …
PET/CT for primary and metastatic pancreatic carcinoma lesions and compare the results …
[HTML][HTML] FAPI PET/CT in the diagnosis of abdominal and pelvic tumors
T Yang, L Ma, H Hou, F Gao, W Tao - Frontiers in Oncology, 2022 - frontiersin.org
Positron emission tomography/computed tomography (PET/CT) with 18F-
fluorodeoxyglucose (18F-FDG) is currently a standard imaging examination used in clinical …
fluorodeoxyglucose (18F-FDG) is currently a standard imaging examination used in clinical …
Imaging Assessment of Pancreatic Cancer Resectability After Neoadjuvant Therapy: AJR Expert Panel Narrative Review
EV Soloff, MM Al-Hawary, TS Desser… - American Journal of …, 2022 - Am Roentgen Ray Soc
Despite important innovations in the treatment of pancreatic ductal adenocarcinoma
(PDAC), PDAC remains a disease with poor prognosis and high mortality. A key area for …
(PDAC), PDAC remains a disease with poor prognosis and high mortality. A key area for …
[HTML][HTML] Impact of FAPI-PET/CT on target volume definition in radiation therapy of locally recurrent pancreatic cancer
J Liermann, M Syed, E Ben-Josef, K Schubert… - Cancers, 2021 - mdpi.com
Simple Summary We demonstrate how manual target definition based on contrast-
enhanced computed tomography is highly unreliable and inconsistent. In a second step, we …
enhanced computed tomography is highly unreliable and inconsistent. In a second step, we …
[18F] AlF-NOTA-FAPI-04 PET/CT can predict treatment response and survival in patients receiving chemotherapy for inoperable pancreatic ductal adenocarcinoma
Z Zhu, K Cheng, Z Yun, X Zhang, X Hu, J Liu… - European Journal of …, 2023 - Springer
Purpose We investigated whether uptake of [18F] AlF-NOTA-FAPI-04 on positron emission
tomography/computed tomography (PET/CT) could predict treatment response and survival …
tomography/computed tomography (PET/CT) could predict treatment response and survival …
[HTML][HTML] Safety, tolerability, and effectiveness of the sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin in combination with standard chemotherapy for …
LK Park, KH Lim, J Volkman, M Abdiannia… - Cancer & …, 2023 - Springer
Background Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy. Thus, there
is an urgent need for safe and effective novel therapies. PDAC's excessive reliance on …
is an urgent need for safe and effective novel therapies. PDAC's excessive reliance on …
Dual-Modality Immuno-PET and Near-Infrared Fluorescence Imaging of Pancreatic Cancer Using an Anti–Prostate Stem Cell Antigen Cys-Diabody
Pancreatic cancer has a high mortality rate due to late diagnosis and the tendency to invade
surrounding tissues and metastasize at an early stage. A molecular imaging agent that …
surrounding tissues and metastasize at an early stage. A molecular imaging agent that …
Differentiating benign and malignant pancreatic masses: Ga-68 PSMA PET/CT as a new diagnostic avenue
Objective Differentiation of malignant and benign pancreatic lesions on anatomical imaging
is difficult in some cases with overlapping features. Prostate-specific membrane antigen …
is difficult in some cases with overlapping features. Prostate-specific membrane antigen …
Incidence and risk factors for abdominal occult metastatic disease in patients with pancreatic adenocarcinoma
Background The incidence of occult metastatic disease (OMD) in pancreatic ductal
adenocarcinoma (PDAC) and associated risk factors are largely unknown. Methods We …
adenocarcinoma (PDAC) and associated risk factors are largely unknown. Methods We …
Diagnosis and management of pancreatic adenocarcinoma in the background of chronic pancreatitis: core issues
RA Narkhede, GS Desai, PP Prasad, PK Wagle - Digestive Diseases, 2019 - karger.com
Background: The incidence of pancreatic adenocarcinoma (PDAC) in patients with chronic
pancreatitis (CP) is as high as 5%. It is a commonly encountered diagnostic challenge in …
pancreatitis (CP) is as high as 5%. It is a commonly encountered diagnostic challenge in …